Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Aug 22, 2024

BUY
$65.94 - $99.04 $966,152 - $1.45 Million
14,652 New
14,652 $999,000
Q4 2021

Feb 08, 2022

SELL
$72.5 - $100.68 $18.5 Million - $25.7 Million
-254,921 Reduced 94.56%
14,652 $1.14 Million
Q3 2021

Nov 12, 2021

SELL
$90.24 - $124.05 $386,678 - $531,554
-4,285 Reduced 1.56%
269,573 $25.7 Million
Q2 2021

Aug 11, 2021

SELL
$93.66 - $139.27 $564,395 - $839,241
-6,026 Reduced 2.15%
273,858 $23.8 Million
Q1 2021

May 11, 2021

SELL
$116.57 - $155.01 $5.09 Million - $6.77 Million
-43,682 Reduced 13.5%
279,884 $36.9 Million
Q4 2020

Feb 09, 2021

BUY
$99.61 - $142.12 $333,394 - $475,675
3,347 Added 1.05%
323,566 $42.9 Million
Q3 2020

Nov 12, 2020

SELL
$72.92 - $102.01 $749,544 - $1.05 Million
-10,279 Reduced 3.11%
320,219 $32.6 Million
Q2 2020

Aug 07, 2020

BUY
$55.75 - $92.75 $18.4 Million - $30.7 Million
330,498 New
330,498 $28.7 Million
Q1 2020

May 08, 2020

SELL
$37.9 - $104.44 $4.16 Million - $11.5 Million
-109,770 Closed
0 $0
Q4 2019

Feb 06, 2020

BUY
$77.66 - $99.74 $8.52 Million - $10.9 Million
109,770 New
109,770 $10.2 Million
Q3 2018

Nov 13, 2018

SELL
$48.29 - $80.6 $847,827 - $1.42 Million
-17,557 Closed
0 $0
Q2 2018

Aug 02, 2018

SELL
$37.84 - $69.96 $1.95 Million - $3.61 Million
-51,557 Reduced 74.6%
17,557 $1.05 Million
Q1 2018

May 11, 2018

SELL
$39.82 - $57.53 $336,996 - $486,876
-8,463 Reduced 10.91%
69,114 $2.79 Million
Q4 2017

Feb 09, 2018

SELL
$46.49 - $60.51 $736,355 - $958,417
-15,839 Reduced 16.96%
77,577 $4.08 Million
Q3 2017

Nov 13, 2017

BUY
$37.05 - $47.12 $3.46 Million - $4.4 Million
93,416
93,416 $4.4 Million

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $10.1B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Fiera Capital Corp Portfolio

Follow Fiera Capital Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fiera Capital Corp, based on Form 13F filings with the SEC.

News

Stay updated on Fiera Capital Corp with notifications on news.